EPO published patent application EP3849532A1 for sustained-release pharmaceutical compositions comprising sedative drugs and uses thereof. The application covers liposomal formulations (A61K 9/127) of sedative compounds including those classified under A61K 31/445 and A61K 31/4174, with therapeutic applications for insomnia (A61P 25/20), pain (A61P 25/04), and migraine (A61P 25/06). Applicants are Taiwan Liposome Company, Ltd. and TLC Biopharmaceuticals, Inc., with designated states spanning 32 European countries.

Pharmaceutical companies and drug manufacturers developing sustained-release formulations should review freedom-to-operate implications given this published application. Competitors with overlapping technology may consider filing observations or opposition during the nine-month opposition period following publication. The A1 publication includes the EPO search report, providing visibility into prior art relevant to related technologies.